Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
International Journal of Technology Assessment in Health Care|October 24, 2002
A new index approach to measure lost benefits from progression to blindnessRikard Althin, Mats Lundström, Pontus RoosInternational Journal of Technology Assessment in Health Care|June 29, 2017
EXPLORING PATENT ACTIVITY AND ITS POTENTIAL ASSOCIATION WITH HEALTHCARE OUTCOMES: A CASE STUDY OF OSTOMY PRODUCTS IN SWEDENPaul Samuel Calara, Rikard Althin, Gary Inglese, et al.Scandinavian Journal of Urology|July 6, 2017
Clinical practice of BOTOX® treatment for overactive bladder syndrome in Sweden: an assessment of resource use and external validityKatarina Gralén, Caroline Elmér, Eva Broström, et al.Journal of Glaucoma|November 16, 2006
Considerations in developing model-based economic evaluations of glaucoma treatmentRikard Althin, Daniel T Grima, Ravinder Dhawan, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 19, 2017
Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 PatientsPaul S Calara, Rikard Althin, Katarina Steen Carlsson, et al.Vaccine|May 7, 2022
Acceptance and application of a broad population health perspective when evaluating vaccineUlf Persson, Sara Olofsson, Rikard Althin, et al.BMC Medical Research Methodology|December 14, 2012
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primerRichard J Willke, Zhiyuan Zheng, Prasun Subedi, et al.Seizure|October 28, 2017
Epilepsy in tuberous sclerosis patients in Sweden - Healthcare utilization, treatment, morbidity, and mortality using national register dataKarl-Olof Welin, Peter Carlqvist, Anders Svensson, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 18, 2016
Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World PracticePaul S Calara, Jenny M Norlin, Rikard Althin, et al.Pageof 1